The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Now the president and Johnson, his closest ally in Congress, must solve a complex political math problem. Passing a “big beautiful bill” that tackles everything from retooling energy policy to ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

In India, many kids who work in retail markets have good math skills. They can quickly perform a range of calculations to complete transactions. But as a new study shows, these kids often perform ...

You might have surgery to remove lymph nodes in your tummy (abdomen). These are called the retroperitoneal lymph nodes. This operation is called a retroperitoneal lymph node dissection. This is a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

However, the association of nodal count to survival suggests that it can be utilized as surrogate for quality of resection. Intraoperative frozen biopsy and sentinel lymph nodes technique have not ...